Compare SBGI & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBGI | COLL |
|---|---|---|
| Founded | 1986 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2023 | 2015 |
| Metric | SBGI | COLL |
|---|---|---|
| Price | $14.09 | $34.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $21.80 | ★ $50.83 |
| AVG Volume (30 Days) | ★ 438.9K | 400.6K |
| Earning Date | 05-26-2026 | 05-28-2026 |
| Dividend Yield | ★ 7.22% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | ★ $3,169,000,000.00 | $780,567,000.00 |
| Revenue This Year | $12.59 | $6.07 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.21 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $11.89 | $23.23 |
| 52 Week High | $17.88 | $50.79 |
| Indicator | SBGI | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 16.51 |
| Support Level | $12.92 | $34.30 |
| Resistance Level | $14.32 | $36.20 |
| Average True Range (ATR) | 0.74 | 1.59 |
| MACD | -0.14 | -0.70 |
| Stochastic Oscillator | 21.56 | 2.18 |
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.